Cross-talk mechanism between endothelial cells and hepatocellular carcinoma cells via growth factors and integrin pathway promotes tumor angiogenesis and cell migration

Oncotarget

Volumn 8, Issue 41, 2017, Pages 69577-69593

  Feng, Tang ^a   Yu, Hongchi ^a   Xia, Qing ^a   Ma, Yunlong ^a   Yin, Hongmei ^a   Shen, Yang ^a   Liu, Xiaoheng ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cell migration; Cross talk; Hepatocellular carcinoma cells; Tumor angiogenesis; Vascular endothelial cells

Indexed keywords

EPIDERMAL GROWTH FACTOR; F ACTIN; FOCAL ADHESION KINASE; GROWTH FACTOR; INTEGRIN; PAXILLIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN CDC42; PROTEIN KINASE B; RAC1 PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TALIN; VASCULOTROPIN; VINCULIN;

ARTICLE; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSKELETON; ENDOTHELIUM CELL; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR VASCULARIZATION;

EID: 85030254883     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.18632     Document Type: Article

References (53)

1. Portillo-Lara R, Annabi N. Microengineered cancer-on-achip platforms to study the metastatic microenvironment. Lab Chip. 2016; 16:4063-81. doi: 10.1039/c6lc00718j.
2. Manzi M, Bacigalupo ML, Carabias P, Elola MT, Wolfenstein-Todel C, Rabinovich GA, Espelt MV, Troncoso MF. Galectin-1 controls the proliferation and migration of liver sinusoidal endothelial cells and their interaction with hepatocarcinoma cells. J Cell Physiol. 2016; 231:1522-33. doi: 10.1002/jcp.25244.
3. Maj E, Papiernik D, Wietrzyk J. Antiangiogenic cancer treatment: the great discovery and greater complexity (Review). Int J Oncol. 2016; 49:1773-84. doi: 10.3892/ijo.2016.3709.
4. Almalki SG, Agrawal DK. Effects of matrix metalloproteinases on the fate of mesenchymal stem cells. Stem Cell Res Ther. 2016; 7:129. doi: 10.1186/s13287-016-0393-1.
5. Gutierrez JM, Escalante T, Rucavado A, Herrera C, Fox JW. A comprehensive view of the structural and functional alterations of extracellular matrix by snake venom metalloproteinases (SVMPs): novel perspectives on the pathophysiology of envenoming. Toxins (Basel). 2016; 8: E304. doi: 10.3390/toxins8100304.
6. Gweon EJ, Kim SJ. Resveratrol attenuates matrix metalloproteinase-9 and-2-regulated differentiation of HTB94 chondrosarcoma cells through the p38 kinase and JNK pathways. Oncol Rep. 2014; 32:71-8. doi: 10.3892/or.2014.3192.
7. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65:87-108. doi: 10.3322/caac.21262.
8. Muto J, Shirabe K, Sugimachi K, Maehara Y. Review of angiogenesis in hepatocellular carcinoma. Hepatol Res. 2015; 45:1-9. doi: 10.1111/hepr.12310.
9. Trédan O, Lacroix-Triki M, Guiu S, Mouret-Reynier MA, Barrière J, Bidard FC, Braccini AL, Mir O, Villanueva C, Barthélémy P. Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. Target Oncol. 2015; 10:189-98. doi: 10.1007/s11523-014-0334-9.
10. Yang Y, Zhang Y, Iwamoto H, Hosaka K, Seki T, Andersson P, Lim S, Fischer C, Nakamura M, Abe M, Cao R, Skov PV, Chen F, et al. Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism. Nat Commun. 2016; 7:12680. doi: 10.1038/ncomms12680.
11. Minder P, Zajac E, Quigley JP, Deryugina EI. EGFR regulates the development and microarchitecture of intratumoral angiogenic vasculature capable of sustaining cancer cell intravasation. Neoplasia. 2015; 17:634-49. doi: 10.1016/j.neo.2015.08.002.
12. Eliceiri BP. Integrin and growth factor receptor crosstalk. Circ Res. 2001; 89:1104-10.
13. Campadelli-Fiume G, Collins-McMillen D, Gianni T, Yurochko AD. Integrins as herpesvirus receptors and mediators of the host signalosome. Annu Rev Virol. 2016; 3:215-36. doi: 10.1146/annurev-virology-110615-035618.
14. Multhaupt HA, Leitinger B, Gullberg D, Couchman JR. Extracellular matrix component signaling in cancer. Adv Drug Deliv Rev. 2016; 97:28-40. doi: 10.1016/j. addr.2015.10.013.
15. Yang C, Zeisberg M, Lively JC, Nyberg P, Afdhal N, Kalluri R. Integrin a1β1 and a2β1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment. Cancer Res. 2003, 63:8312-7.
16. Li YS, Haga JH, Chien S. Molecular basis of the effects of shear stress on vascular endothelial cells. J Biomech. 2005; 38:1949-71. doi: 10.1016/j.jbiomech.2004.09.030.
17. Akeson A, Herman A, Wiginton D, Greenberg J. Endothelial cell activation in a VEGF-A gradient: relevance to cell fate decisions. Microvasc Res. 2010; 80:65-74. doi: 10.1016/j. mvr.2010.02.001.
18. Reinehr R, Gohlke H, Sommerfeld A, Vom Dahl S, Haussinger D. Activation of integrins by urea in perfused rat liver. J Biol Chem. 2010; 285:29348-56. doi: 10.1074/jbc.M110.155135.
19. Ruoslahti E. Specialization of tumour vasculature. Nat Rev Cancer. 2002; 2:83-90. doi: 10.1038/nrc724.
20. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006; 6:449-58. doi: 10.1038/nrc1886.
21. Lawson C, Lim ST, Uryu S, Chen XL, Calderwood DA, Schlaepfer DD. FAK promotes recruitment of talin to nascent adhesions to control cell motility. J Cell Biol. 2012; 196:223-32. doi: 10.1083/jcb.201108078.
22. Parsons JT, Horwitz AR , Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. Nat Rev Mol Cell Biol. 2010; 11:633-43. doi: 10.1038/nrm2957.
23. Jain RK. Determinants of tumor blood flow: a review. Cancer Res. 1988; 48:2641-58.
24. Ding Q, Xia Y, Ding S, Lu P, Sun L, Fan Y, Li X, Wang Y, Tian DA, Liu M. Potential role of CXCL9 induced by endothelial cells/CD133+liver cancer cells co-culture system in tumor transendothelial migration. Genes Cancer. 2016; 7:254-59. doi:10.18632/genesandcancer.116.
25. Luo Q, Song G, Song Y, Xu B, Qin J, Shi Y. Indirect co-culture with tenocytes promotes proliferation and mRNA expression of tendon/ligament related genes in rat bone marrow mesenchymal stem cells. Cytotechnology. 2009; 61:1-10. doi: 10.1007/s10616-009-9233-9.
26. Warner KA, Miyazawa M, Cordeiro MM, Love WJ, Pinsky MS, Neiva KG, Spalding AC, Nör JE. Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. Neoplasia. 2008; 10:131-9.
27. Zhou K, Sun P, Zhang Y, You X, Li P, Wang T. Estrogen stimulated migration and invasion of estrogen receptornegative breast cancer cells involves an ezrin-dependent crosstalk between G protein-coupled receptor 30 and estrogen receptor beta signaling. Steroids. 2016; 111:113-20. doi: 10.1016/j.steroids.2016.01.021.
28. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011; 147:275-92. doi: 10.1016/j.cell.2011.09.024.
29. Overall CM, López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002; 2:657-72. doi: 10.1038/nrc884.
30. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-74. doi: 10.1016/j. cell.2011.02.013.
31. Kareva I, Abou-Slaybi A, Dodd O, Dashevsky O, Klement GL. Normal wound healing and tumor angiogenesis as a game of competitive inhibition. PloS One. 2016; 11:e0166655. doi: 10.1371/journal.pone.0166655. eCollection 2016.
32. Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M , Sood AK. Monocyte subpopulations in angiogenesis. Cancer Res. 2014; 74:1287-93. doi: 10.1158/0008-5472.CAN-13-2825.
33. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011; 17:1359-70. doi: 10.1038/nm.2537.
34. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol. 2011; 27:563-84. doi: 10.1146/annurev-cellbio-092910-154002.
35. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15:232-9. doi: 10.1016/j. ccr.2009.01.021.
36. Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013; 13:871-82. doi: 10.1038/nrc3627.
37. Welti J, Loges S, Dimmeler S, Carmeliet P. Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest. 2013; 123:3190-200. doi: 10.1172/JCI70212.
38. Greenberg JI, Shields DJ, Barillas SG, Acevedo LM, Murphy E, Huang J, Scheppke L, Stockmann C, Johnson RS, Angle N, Cheresh DA. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008; 456:809-13. doi: 10.1038/nature07424.
39. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res. 2001; 61:2736-43.
40. Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G, Min W. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest. 2016; 126:4157-73. doi: 10.1172/JCI87252.
41. Neiva KG, Zhang Z, Miyazawa M, Warner KA, Karl E, Nör JE. Cross talk initiated by endothelial cells enhances migration and inhibits anoikis of squamous cell carcinoma cells through STAT3/Akt/ERK signaling. Neoplasia. 2009; 11:583-93.
42. Ding Q, Xia Y, Ding S, Lu P, Sun L, Fan Y, Li X, Wang Y, Tian DA, Liu M. Potential role of CXCL9 induced by endothelial cells/CD133+ liver cancer cells co-culture system in tumor transendothelial migration. Genes Cancer. 2016; 7:254-9. doi: 10.18632/genesandcancer.116.
43. Yu H, Kortylewski M , Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007; 7:41-51. doi: 10.1038/nri1995.
44. Bill HM, Knudsen B, Moores SL, Muthuswamy SK, Rao VR, Brugge JS, Miranti CK. Epidermal growth factor receptor-dependent regulation of integrin-mediated signaling and cell cycle entry in epithelial cells. Mol Cell Biol. 2004; 24:8586-99. doi:10.1128/MCB.24.19.8586-8599.2004.
45. Alam N, Goel HL, Zarif MJ, Butterfield JE, Perkins HM, Sansoucy BG, Sawyer TK , Languino LR. The integrin-growth factor receptor duet. J Cell Physiol. 2007; 213:649-53. doi: 10.1002/jcp.21278.
46. Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res. 2010; 339:269-80. doi: 10.1007/s00441-009-0834-6.
47. Hynes RO. Integrins: Bidirectional, allosteric signaling machines. Cell. 2002; 110:673-87.
48. Legate KR, Wickström SA, Fässler R. Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev. 2009; 23:397-418. doi: 10.1101/gad.1758709.
49. Ivaska J , Heino J. Interplay between cell adhesion and growth factor receptors: from the plasma membrane to the endosomes. Cell Tissue Res. 2010; 339:111-20. doi: 10.1007/s00441-009-0857-z.
50. Hannigan G, Troussard AA , Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer. 2005; 5:51-63. doi: 10.1038/nrc1524.
51. Liu X, Schnellmann RG. Calpain mediates progressive plasma membrane permeability and proteolysis of cytoskeleton-associated paxillin, talin, and vinculin during renal cell death. J Pharmacol Exp Ther. 2003; 304:63-70. doi: 10.1124/jpet.102.043406.
52. Wiesner S, Legate KR, Fässler R. Integrin-actin interactions. Cell Mol Life Sci. 2005; 62:1081-99. doi: 10.1007/s00018-005-4522-8.
53. Varga A, Gyulavári P, Greff Z, Futosi K, Németh T, Simon-Szabó L, Kerekes K, Szántai-Kis C, Brauswetter D, Kokas M, Borbély G, Erdei A, Mócsai A, et al. Targeting vascular endothelial growth factor receptor 2 and protein kinase D1 related pathways by a multiple kinase inhibitor in angiogenesis and inflammation related processes in vitro. PloS One. 2015; 10:e0124234. doi: 10.1371/journal. pone.0144792. eCollection 2015.